Assembly Biosciences Share Holder Equity 2010-2024 | ASMB

Assembly Biosciences share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Assembly Biosciences Annual Share Holder Equity
(Millions of US $)
2023 $41
2022 $83
2021 $169
2020 $241
2019 $273
2018 $211
2017 $113
2016 $80
2015 $119
2014 $59
2013 $24
2012 $18
2011 $35
2010 $12
2009 $-13
Assembly Biosciences Quarterly Share Holder Equity
(Millions of US $)
2024-06-30 $35
2024-03-31 $33
2023-12-31 $41
2023-09-30 $42
2023-06-30 $55
2023-03-31 $70
2022-12-31 $83
2022-09-30 $102
2022-06-30 $124
2022-03-31 $147
2021-12-31 $169
2021-09-30 $225
2021-06-30 $232
2021-03-31 $247
2020-12-31 $241
2020-09-30 $271
2020-06-30 $267
2020-03-31 $252
2019-12-31 $273
2019-09-30 $156
2019-06-30 $175
2019-03-31 $190
2018-12-31 $211
2018-09-30 $229
2018-06-30 $89
2018-03-31 $102
2017-12-31 $113
2017-09-30 $47
2017-06-30 $57
2017-03-31 $68
2016-12-31 $80
2016-09-30 $90
2016-06-30 $101
2016-03-31 $109
2015-12-31 $119
2015-09-30 $125
2015-06-30 $131
2015-03-31 $125
2014-12-31 $59
2014-09-30 $47
2014-06-30 $20
2014-03-31 $22
2013-12-31 $24
2013-09-30 $30
2013-06-30 $31
2013-03-31 $35
2012-12-31 $18
2012-09-30 $21
2012-06-30 $26
2012-03-31 $28
2011-12-31 $35
2011-09-30 $52
2011-06-30 $9
2011-03-31 $13
2010-12-31 $12
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31 $-13
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.107B $0.007B
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00